Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

Press Releases

Diagonal Bio AB strengthens its go-to-market strategy through an agreement with founding partner Johan Källstrand

Non-regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or the “Company”) today announces a strategic step to strengthen its sales and marketing efforts. The company has secured the commitment of Johan Källstrand, one of the company’s founders with extensive experience and knowledge within the company’s market areas. The agreement means that Diagonal Bio is supported by Källstrand’s long experience and deep knowledge to strengthen its go-to-market strategy.

Read more

The subscription period in Diagonal Bio AB rights issue commences today

Non-regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) issue of units consisting of shares and consideration free warrants of series TO 1 (”TO 1”), with preferential right for the Company’s existing shareholders begins. The subscription period runs until the 22[nd] of April 2024. The issue volume initially amounts to a maximum of approximately SEK 32 million before transaction costs (the “Rights Issue”). Upon full subscription of the Rights Issue and full utilization of issued TO 1 at the highest subscription price, the Company may receive an additional approximately SEK 9.5 million before transaction costs. The Rights Issue is secured in writing by members of the board, management, existing shareholders, and external investors to a total of approximately 56.4 percent (corresponding to approximately SEK 18 million) through pre-subscription and guarantee commitments. A prospectus is available via the Company’s (www.diagonalbio.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) websites. The Company’s will today, the 8[th] of April 2024, present at an event with Financial Stockholm at Scandic Klara Hotell.

Read more

Diagonal Bio AB (publ) genomför en effektivisering av marknadskommunikation och ändrar från svenska till engelska för pressreleaser och delårsrapporter.

Non-regulatory

Diagonal Bio (“Bolaget”) meddelar att Bolaget valt att effektivisera sin marknadskommunikation och framöver endast kommer att tillhandahålla pressmeddelanden och delårsrapporter på engelska. Diagonal Bios årsredovisningar kommer även fortsättningsvis publiceras på svenska.

Read more

Valberedning utsedd i Diagonal Bio AB (publ.) inför årsstämman 2024

Non-regulatory

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2023, har följande valberedning utsetts för Diagonal Bio AB (publ.) inför årsstämman 2024.

Read more

Rättelse avseende felaktigt utskick av pressmeddelande

Non-regulatory

Rättelse:  2023-11-27 kl 10:11:38 skickade Bolaget felaktigt ut ett tidigare publicerat press meddelande från 2023-03-06.

Read more

Board

Kerstin Åkesson Jakobsson

Chair of the Board since 2023

On the board since: 2021

Background and Education: Kerstin Åkesson Jakobsson is a civil engineer with over 30 years of experience in marketing and sales, primarily in the Medtech sector, as well as in corporate management and business development. She has served as CEO for development companies such as SpectraCure AB and Ortoma AB, and CEO for Medicon Village Innovation. Jakobsson has also completed board training at EFL and the Board Academy.

Current Engagements: Senior Advisory of Kongsberg Beam Technology AS and CEO and chairman of Krakesson AB. Board member of the Stiftelsen TEM, QueenInvest AB, and OctaQuest AB.

Holdings in the Company:
Kerstin Jakobsson owns 19,045 shares.
Krakesson AB holds 240,516 shares.

Independent in relation to the Company and its management / major shareholders of the Company: Yes / No

Karin Wehlin

Board Member

On the board since: 2023

Background and Education: Karin Wehlin has an Executive MBA degree from Lunds University and educated at INSEAD in Strategy, Innovation, and Leadership. Karin has over 25 years of experience in senior positions within the Life Science sector. She has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB, as well as a Manager in Corporate Finance. Karin is also the founder of EQL Pharma AB, where she was the executive Chairman of the board for 10 years.

Current Engagements: Chair of the Board at Duearity AB and Respiratorius AB.

Holdings in the Company:
0 shares

Independent in relation to the Company and its management / major shareholders of the Company: No / Yes

Edvard Hall

Board Member

On the board since: 2021

Background and Education: Edvard Hall holds degrees in economics and law and is an entrepreneur with extensive experience in building and managing companies within the sustainability sector. Hall also has a master’s degree in political economy from the London School of Economics.

Current Engagements: CEO of Bioextrax AB (publ), Chairman of the Board for ProLevi Bio AB and Könvyes Invest AB, and Board Member of Parlametric AB.

Holdings in the Company: 358,000 shares and private capital invested in the Company.

Independent in relation to the Company and its management / major shareholders of the Company: Yes / Yes

Kushagr Punyani

Board Member

On the board since: 2020

Background and Education: Kushagr Punyani is educated in microfluidics and biosensors. Punyani has co-founded several startups in the tech industry alongside his role as Chief Scientific Officer (CSO) at Spermosens AB, a company specializing in diagnostic equipment and products for male fertility diagnostics and treatment.

Current Engagements: Board member at Spermosens AB, Prolevi Bio AB and Nested Bio AB.

Holdings in the Company:
Kushagr Punyani owns 1,876,000 shares and has private capital invested in the Company.
Nested Bio AB holds 110,292 shares.

Independent in relation to the Company and its management / major shareholders of the Company: Yes / No

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Executive Management

Karin Wehlin

CEO since November 2023
Board Member since 2023

Learn more about her background and other engagements above.

Per Heander

CFO since 2021

Background and Education: Per Heander holds a degree in Business Administration from Lund University and has 20 years of experience as an Investment Manager in venture capital, with extensive experience in developing young growth companies and serving as a board member. Heander has served as CFO for various companies including Invent Medic, Bomill, and Benchtell AB. He also brings 10 years of experience from different positions within SEB.

Current Engagements: Board member at Gand AB, board member and CEO of Treeridge AB, and deputy board member of Fyra X Invest AB.

Holdings in the Company:
Per Heander owns 104,755 shares, of which 47,615 are through capital insurance.
Treeridge AB holds 473,677 shares.

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 770 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 11 32 30 732
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö